The first domestic ADC drug has been fully approved for marketing in China

On November 27th, Sichuan Kolombotec Biopharmaceutical Joint Stock Company announced that the company's first domestic antibody drug conjugate (ADC) targeting TROP2 for adult patients with unresectable locally advanced or metastatic triple negative breast cancer who have received at least two previous systemic therapies was approved by the State Drug Administration (NMPA) for listing in China. This is the first domestic TROP2ADC to be approved for listing in China, and it is also the first domestic ADC to be fully approved for listing in China. Boosted by this news, Kolombotec (06990.HK) shares rose more than 5.5%.